NCT06980545View on ClinicalTrials.gov

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

May 30, 2028

Conditions
Stage III and IV Ovarian Cancer
Interventions
DRUG

Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)

Neoadjuvant chemotherapy (Paclitaxel and Carboplatin) will be given in complete six cycles

All Listed Sponsors
lead

Assiut University

OTHER